股本结构
单位：万股
| 公告日期 | 2026-10-16 | 2026-10-16 | 2026-10-08 | 2026-10-16 | 2026-08-27 | 2026-08-27 |
|---|---|---|---|---|---|---|
| 证券总股本 | 215.56 | 209.57 | 194.78 | 128.57 | 128.56 | 3214.06 |
| 普通股本 | 215.56 | 209.57 | 194.78 | 128.57 | 128.56 | 3214.06 |
| 优先股 | 未披露 | 未披露 | 未披露 | 1.46 | 未披露 | 未披露 |
| 其他 | 未披露 | 未披露 | 未披露 | 未披露 | 未披露 | 未披露 |
| 变动日期 | 2026-10-15 | 2026-10-13 | 2026-10-05 | 2026-09-15 | 2026-08-31 | 2026-08-24 |
注释：中概股证券总股本=普通股股本/
存托凭证比例
历史变动
| 公告日期 | 变动后普通股本（万股） | 变动后优先股（万股） | 变动原因 | 变动日期 |
|---|---|---|---|---|
| 2026-10-16 | 215.56 | 未披露 | 定期报告 | 2026-10-15 |
| 2026-10-16 | 209.57 | 未披露 | 定期报告 | 2026-10-13 |
| 2026-10-08 | 194.78 | 未披露 | 定期报告 | 2026-10-05 |
| 2026-10-16 | 128.57 | 1.46 | 定期报告 | 2026-09-15 |
| 2026-08-27 | 128.56 | 未披露 |
更多>>
a 1-for-25 reverse stock split of the Company's issued and outstanding shares of common stock
|
2026-08-31 |
| 2026-08-27 | 3214.06 | 未披露 | 定期报告 | 2026-08-24 |
| 2026-08-14 | 2218.97 | 未披露 | 定期报告 | 2026-08-13 |
| 2026-08-14 | 415.19 | 1.42 |
更多>>
From March 31, 2026 to June 30, 2026
Issuance of preferred stock and warrants, net of issuance costs
Conversion of Series B preferred stock into common stock
Conversion of Series C preferred stock into common stock
Issuance of common stock for equity line of credit
Settlement of restricted stock units
Exercise of warrants
|
2026-06-30 |
| 2026-05-14 | 320.08 | 未披露 | 定期报告 | 2026-05-10 |
| 2026-04-30 | 313.91 | 未披露 | 定期报告 | 2026-04-24 |
| 2026-05-14 | 287.99 | 1.43 |
更多>>
From January 1,2026 to March 31,2026
Conversion of Series C preferred stock into common stock
Settlement of restricted stock units
|
2026-03-31 |
| 2026-03-30 | 287.79 | 未披露 | 定期报告 | 2026-03-17 |
| 2026-03-30 | 252.58 | 1.46 |
更多>>
From December 31, 2024 to December 31, 2025
Issuance of Series B preferred stock and warrants, net of issuance costs and warrants to placement agents
Issuance of Series C preferred stock and warrants, net of issuance costs and warrants to placement agents
Issuance of common stock and preferred stock, net of issuance costs
Issuance of common stock for equity line of credit
Issuance of common stock in lieu of fractional shares for stock split
Settlement of restricted stock units
Exercise of warrants
Conversion of Series A preferred stock into common stock
Conversion of Series B preferred stock into common stock
|
2025-12-31 |
| 2025-12-29 | 252.58 | 未披露 | 定期报告 | 2025-12-26 |
| 2025-11-14 | 176.60 | 未披露 | 定期报告 | 2025-11-12 |
| 2025-10-17 | 169.57 | 未披露 | 定期报告 | 2025-10-15 |
| 2025-11-14 | 166.29 | 0.40 |
更多>>
From June 30, 2025 to September 30, 2025
Issuance of common stock, net of issuance costs
Settlement of restricted stock units
Conversion of preferred stock into common stock
|
2025-09-30 |
| 2025-08-29 | 157.42 | 未披露 | 定期报告 | 2025-08-27 |
| 2025-08-08 | 108.30 | 未披露 | 定期报告 | 2025-08-05 |
| 2025-07-25 | 104.08 | 未披露 | 定期报告 | 2025-07-23 |
| 2025-08-14 | 96.59 | 0.12 |
更多>>
From March 31, 2025 to June 30, 2025
Issuance of common stock, net of issuance costs
Issuance of preferred stock and common stock warrants, net of issuance costs and warrants to placement agents
|
2025-06-30 |
| 2025-06-06 | 96.59 | 未披露 | 定期报告 | 2025-06-04 |
| 2025-06-02 | 87.83 | 未披露 | 定期报告 | 2025-04-29 |
| 2025-05-15 | 70.56 | 0.05 |
更多>>
From January 1, 2025 to March 31, 2025
Issuance of stock for consideration of licensed technology
Issuance of common stock for equity line of credit
Issuance of common stock in lieu of fractional shares for stock split
Exercise of warrants
|
2025-03-31 |
| 2025-03-21 | 62.01 | 未披露 | 定期报告 | 2025-03-17 |
| 2025-03-05 | 55.69 | 未披露 |
更多>>
a 1-for-17 reverse stock split of the Company’s issued and outstanding shares of common stock
|
2025-03-07 |
| 2025-01-03 | 946.73 | 未披露 | 定期报告 | 2024-12-20 |
| 2024-11-14 | 826.61 | 未披露 | 定期报告 | 2024-11-12 |
| 2024-11-14 | 624.34 | 未披露 |
更多>>
From June 30, 2024 to September 30, 2024
Issuance of common stock
|
2024-09-30 |
| 2024-08-14 | 618.36 | 未披露 |
更多>>
From March 31, 2024 to June 30, 2024
Issuance of common stock and warrants, net of issuance costs and warrants issued to placement agents
|
2024-06-30 |
| 2024-05-15 | 618.36 | 未披露 | 定期报告 | 2024-05-14 |
| 2024-05-15 | 147.36 | 未披露 |
更多>>
From January 1, 2024 to March 31, 2024
Issuance of common stock for restricted stock award
|
2024-03-31 |
| 2023-11-14 | 146.61 | 未披露 |
更多>>
From June 30, 2023 to September 30, 2023
Issuance of common stock, net of issuance costs
Issuance of fractional shares
|
2023-09-30 |
| 2023-08-22 | 146.60 | 未披露 |
更多>>
Tivic Health Systems, Inc. announced that its Board of Directors has declared a 1-for-100 reverse stock split of the company’s issued and outstanding shares of common stock.
|
2023-08-23 |
| 2023-08-08 | 14660.07 | 未披露 |
更多>>
Common Stock offered 33,173,000 shares by the company
|
2023-08-09 |
| 2023-07-17 | 11342.77 | 未披露 |
更多>>
Common Stock offered 51,250,000 shares by the company
|
2023-07-19 |
| 2023-07-11 | 6217.77 | 未披露 |
更多>>
Common Stock offered by the company 32,500,000 shares
|
2023-07-11 |
| 2023-05-15 | 2967.77 | 未披露 |
更多>>
From January 1, 2023 to March 31, 2023
Issuance of common stock, net of issuance costs
|
2023-03-31 |
| 2023-02-10 | 2967.77 | 未披露 |
更多>>
Common stock offered 20,000,000 shares by the company
|
2023-02-13 |
| 2022-12-20 | 967.77 | 未披露 | 定期报告 | 2022-12-15 |
| 2022-11-14 | 967.77 | 未披露 | 定期报告 | 2022-11-09 |
| 2022-10-26 | 967.93 | 未披露 | 定期报告 | 2022-10-05 |
| 2022-11-14 | 967.77 | 未披露 |
更多>>
From June 30, 2022 to September 30, 2022
Exercise of stock options
|
2022-09-30 |
| 2022-08-15 | 967.77 | 未披露 | 定期报告 | 2022-07-28 |
| 2022-08-15 | 962.15 | 未披露 |
更多>>
From March 31, 2022 to June 30, 2022
Repurchase of restricted common stock
|
2022-06-30 |
| 2022-05-02 | 962.15 | 未披露 | 定期报告 | 2022-04-18 |
| 2022-03-31 | 971.52 | 未披露 |
更多>>
From December 31, 2020 to December 31, 2021
Conversion of convertible preferred stock to common stock
Conversion of convertible notes payable to common stock
Issuance of common stock, net of issuance costs
Exercise of stock options
|
2021-12-31 |
| 2021-11-15 | 971.52 | 未披露 |
更多>>
1.The Company has granted the underwriters a 45-day option to purchase up to 450,000 additional Shares to cover over-allotments.
2.The number of common stock to be outstanding prior to and after this offering is based on 9,265,234 the actual number of shares outstanding as of November 11, 2021
|
2021-11-15 |
| 2021-11-12 | 926.52 | 未披露 |
更多>>
1.Common stock offered by company 3,000,000 shares.
|
2021-11-11 |
a 1-for-25 reverse stock split of the Company's issued and outstanding shares of common stock
From March 31, 2026 to June 30, 2026
Issuance of preferred stock and warrants, net of issuance costs
Conversion of Series B preferred stock into common stock
Conversion of Series C preferred stock into common stock
Issuance of common stock for equity line of credit
Settlement of restricted stock units
Exercise of warrants
From January 1,2026 to March 31,2026
Conversion of Series C preferred stock into common stock
Settlement of restricted stock units
From December 31, 2024 to December 31, 2025
Issuance of Series B preferred stock and warrants, net of issuance costs and warrants to placement agents
Issuance of Series C preferred stock and warrants, net of issuance costs and warrants to placement agents
Issuance of common stock and preferred stock, net of issuance costs
Issuance of common stock for equity line of credit
Issuance of common stock in lieu of fractional shares for stock split
Settlement of restricted stock units
Exercise of warrants
Conversion of Series A preferred stock into common stock
Conversion of Series B preferred stock into common stock
From June 30, 2025 to September 30, 2025
Issuance of common stock, net of issuance costs
Settlement of restricted stock units
Conversion of preferred stock into common stock
From March 31, 2025 to June 30, 2025
Issuance of common stock, net of issuance costs
Issuance of preferred stock and common stock warrants, net of issuance costs and warrants to placement agents
From January 1, 2025 to March 31, 2025
Issuance of stock for consideration of licensed technology
Issuance of common stock for equity line of credit
Issuance of common stock in lieu of fractional shares for stock split
Exercise of warrants
a 1-for-17 reverse stock split of the Company’s issued and outstanding shares of common stock
From June 30, 2024 to September 30, 2024
Issuance of common stock
From March 31, 2024 to June 30, 2024
Issuance of common stock and warrants, net of issuance costs and warrants issued to placement agents
From January 1, 2024 to March 31, 2024
Issuance of common stock for restricted stock award
From June 30, 2023 to September 30, 2023
Issuance of common stock, net of issuance costs
Issuance of fractional shares
Tivic Health Systems, Inc. announced that its Board of Directors has declared a 1-for-100 reverse stock split of the company’s issued and outstanding shares of common stock.
Common Stock offered 33,173,000 shares by the company
Common Stock offered 51,250,000 shares by the company
Common Stock offered by the company 32,500,000 shares
From January 1, 2023 to March 31, 2023
Issuance of common stock, net of issuance costs
Common stock offered 20,000,000 shares by the company
From June 30, 2022 to September 30, 2022
Exercise of stock options
From March 31, 2022 to June 30, 2022
Repurchase of restricted common stock
From December 31, 2020 to December 31, 2021
Conversion of convertible preferred stock to common stock
Conversion of convertible notes payable to common stock
Issuance of common stock, net of issuance costs
Exercise of stock options
1.The Company has granted the underwriters a 45-day option to purchase up to 450,000 additional Shares to cover over-allotments.
2.The number of common stock to be outstanding prior to and after this offering is based on 9,265,234 the actual number of shares outstanding as of November 11, 2021
1.Common stock offered by company 3,000,000 shares.